Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) on Friday announced positive results from the REDEFINE 1 phase 3 trial of CagriSema, a fixed-dose combination of cagrilintide and semaglutide.

The trial included 3,417 randomised people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg. It demonstrated superior weight loss with CagriSema compared to individual components or placebo.

Results showed that people treated with CagriSema achieved a superior weight loss of 22.7% after 68 weeks compared with a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone. In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo.

The treatment was generally safe and well-tolerated.

A second pivotal phase 3 trial, REDEFINE 2, is being conducted in adults with type 2 diabetes and either obesity or overweight, with results expected in the first half of 2025.